In brief: Eqitx, Stirling Products
Monday, 12 July, 2004
Two Perth-based biotechs have made key executive appointments.
Drug development company Eqitx (ASX:EQX) has former CSL and Amrad business development executive Joy Hewitt as its chief commercialisation officer.
At CSL, Hewitt was R&D and pharmaceuticals business development manager, where her responsibilities included commercialising CSL projects, evaluating and securing R&D opportunities, and in-licensing pharmaceutical products for domestic and NZ markets. Eqitx said Hewitt had also acted as a consultant to Australian research, biotech and medical organisations.
Animal growth promoter specialist Stirling Products (ASX:STI) has appointed Murray Ward, a stockbroker with 20 years' experience, as an executive director.
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
